Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Methoxyflurane→

Methoxyflurane Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
76-38-0
Molecular formula
C3H4Cl2F2O
Molecular weight
164.96 g/mol
Drug class
Volatile fluorinated hydrocarboninhaled analgesic
Mechanism of action
The precise analgesic mechanism is not fully elucidated. At low inhaled concentrations, methoxyflurane acts through multiple neuronal mechanisms, including effects on neurotransmitter release and uptake, ion conductance and inhibitory GABA signalling.
Indications / reported uses
  • Emergency relief of moderate-to-severe pain in conscious patients aged 6 years and older with trauma and associated pain, using the authorised inhaler product.

Sources: https://www.medicines.org.uk/emc/product/1939/smpc · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/methoxyflurane

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Methoxyflurane Environmental Risk Assessment (ERA) (the Methoxyflurane ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.